Biogen Inc

Pharmaceuticals
BIIB
$ 198 (1.4)%
Share price
$ 29 bn
Market Cap
$ 31 bn
Enterprise Value

Carbon footprint

3.1 Ton
GHG emissions per $ 1 mln investment
0.08x the weighted average for S&P 500
FY2021
How is this calculated?
+3.1%
YOY change in GHG emissions
Weaker than the +4.9% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-4.7%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

Biogen Inc aims to reduce Scope 1 + 2 by 55% by 2032 from a base year 2019


1.5°C
Biogen Inc's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Biogen Inc's GHG emissions (location-based) (Kt of CO2e)
Biogen Inc's Carbon intensity (Tons per 1 USDm)

Biogen Inc's carbon footprint

Biogen Inc reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 97 Kt (+2.9/+3.1% y-o-y). Carbon intensity also surged to 8.9 t (+1.9/+27% y-o-y).

Biogen Inc's Scope 3 emissions increased to 406 Kt (+58/+16% y-o-y). The parameter has been fairly volatile.

The company is committed to reducing Scope 1 + 2 by 55% by 2032 from a base year 2019, which translates into the estimated reduction of -4.6 Kt per annum over the period of FY2022 - FY2032. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Company environmental metrics

Show more...